Based on the key indicators related to Seelos Therapeutics' liquidity, profitability, solvency, and operating efficiency, Seelos Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.
With this module, you can analyze Seelos financials for your investing period. You should be able to track the changes in Seelos Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Seelos
The data published in Seelos Therapeutics' official financial statements typically reflect Seelos Therapeutics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Seelos Therapeutics' quantitative information. For example, before you start analyzing numbers published by Seelos accountants, it's essential to understand Seelos Therapeutics' liquidity, profitability, and earnings quality within the context of the Pharmaceuticals space in which it operates.
Seelos Therapeutics Stock Summary
Seelos Therapeutics competes with ATAI Life, Mind Medicine, GH Research, Cybin, and Pulmatrix. Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York. Seelos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people.
There are many critical financial ratios that Seelos Therapeutics' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Seelos Therapeutics reports annually and quarterly.
Comparative valuation techniques use various fundamental indicators to help in determining Seelos Therapeutics's current stock value. Our valuation model uses many indicators to compare Seelos Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Seelos Therapeutics competition to find correlations between indicators driving Seelos Therapeutics's intrinsic value. More Info.
Seelos Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Seelos Therapeutics' earnings, one of the primary drivers of an investment's value.
Seelos Therapeutics Market Pulse
Quote
0.39
Change(%)
22.00
Change
0.11
Open
0.5
Low
0.37
High
0.5
Volume
0
Exchange
OTCQB
Seelos Therapeutics December 17, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Seelos Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Seelos Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Seelos Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Seelos OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Seelos Therapeutics's daily price indicators and compare them against related drivers.
Other Information on Investing in Seelos OTC Stock
Seelos Therapeutics financial ratios help investors to determine whether Seelos OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Seelos with respect to the benefits of owning Seelos Therapeutics security.